YWHAG Genetic Variant Pediatric Genome Analysis provides a starting point for the design of customized treatments
사진 확대 Images related to 3Billion’s YWHAG gene mutation child genomic analysis support. Photograph = Three Billionaires
Three Billion, an artificial intelligence (AI)-based rare genetic disease diagnostic company, announced on the 26th that it will cooperate with the U.S. non-profit organization “N=1 Collaborative (N1C) to support precise dielectric analysis of children with ultra-rare YWHAG gene mutations.
The target of this support is James, a 5-year-old boy living in California, USA, who has a YWHAG mutation that causes seizures and developmental delays. There is no approved treatment for the ultra-rare disease, which has only about 50 reported cases worldwide, causing great difficulties for children and their families.
Three Billionaire used high-resolution WGS analysis and AI-based genetic mutation analysis technology to precisely analyze James’ DNA. Key information that can target mutated genes was derived and provided to N1C, setting the starting point for customized treatment design.
N1C is the world’s first organization to receive US Food and Drug Administration (FDA) approval for a single patient-specific new drug “Milasen” in 2019, creating a global cooperative ecosystem that leads to the development of customized treatments for ultra-rare diseases.
Again, based on the results of the Three Billion analysis, we will promote the design of an ASO (Antisense Oligonucleotide) treatment for James with global clinical trial trustee (CRO) Charles River.
CEO Geum Chang-won said, “It is meaningful to join the support for James with N1C. We will continue to fulfill our social responsibility to open up new possibilities for patients with rare diseases with AI technology.”